Within the type taxonomy, the market is further stratified into four sub‑categories: herbal formulas, patented Chinese medicines, decoctions, and nutraceutical supplements. Herbal formulas are multi‑herb mixtures prepared according to classical recipes such as Lianhua Qingwen and Shuanghuanglian; they generate the largest share of type‑level revenue, estimated at 40 % of the overall market, because of their established efficacy and broad regulatory acceptance. Patented Chinese medicines are standardized, factory‑produced tablets or capsules that combine traditional ingredients with modern quality controls; they hold roughly 35 % of market value, reflecting strong demand from institutional buyers seeking consistent dosing. Decoctions are patient‑specific, water‑extracted preparations prepared in clinical settings; they account for about 20 % of sales, primarily in tertiary hospitals where individualized therapy is emphasized. Nutraceutical supplements, including isolated active compounds like glycyrrhizin or flavonoid extracts, represent the remaining 5 % and are growing slowly as consumer‑direct channels expand. This type‑level breakdown complements the application‑level view in the Traditional Chinese Medicine for COVID-19 segmentation framework.